ADIA Nutrition Inc Appoints First Doctor of Its Medical Division
ADIA Nutrition Inc (OTC Pink: ADIA) has appointed Dr. Monica Sher as one of the Directors of its Medical Division. Dr. Sher will play a important role in establishing policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients. With her background in Internal Medicine, Dr. Sher brings extensive experience to advance aHSCT therapies for MS.
In a notable arrangement, Dr. Sher will receive equity in the company instead of a salary, demonstrating her commitment to ADIA's success. She will be compensated per procedure performed. CEO Larry Powalisz expressed confidence that Dr. Sher's expertise will be invaluable as ADIA expands its medical division and aims to provide top-tier care to MS patients.
ADIA Nutrition Inc (OTC Pink: ADIA) ha nominato la Dott.ssa Monica Sher come uno dei Direttori della sua Divisione Medica. La Dott.ssa Sher avrà un ruolo fondamentale nell'istituire politiche e procedure per il programma di Trapianto di Cellule Staminali Ematopoietiche Autologhe (aHSCT) per pazienti affetti da Sclerosi Multipla (SM). Con la sua formazione in Medicina Interna, la Dott.ssa Sher porta con sé una vasta esperienza per avanzare le terapie aHSCT per la SM.
In un accordo significativo, la Dott.ssa Sher riceverà una partecipazione azionaria nell'azienda invece di uno stipendio, dimostrando il suo impegno per il successo di ADIA. Sarà compensata per ciascuna procedura eseguita. Il CEO Larry Powalisz ha espresso fiducia che l'esperienza della Dott.ssa Sher sarà inestimabile mentre ADIA espande la sua divisione medica e punta a fornire assistenza di alto livello ai pazienti con SM.
ADIA Nutrition Inc (OTC Pink: ADIA) ha designado a la Dra. Monica Sher como una de las Directoras de su División Médica. La Dra. Sher desempeñará un papel importante en el establecimiento de políticas y procedimientos para el programa de Transplante de Células Madre Hematopoyéticas Autólogas (aHSCT) para pacientes con Esclerosis Múltiple (EM). Con su formación en Medicina Interna, la Dra. Sher aporta una amplia experiencia para avanzar en las terapias aHSCT para la EM.
En un acuerdo notable, la Dra. Sher recibirá acciones de la empresa en lugar de un salario, demostrando su compromiso con el éxito de ADIA. Se le compensará por cada procedimiento realizado. El CEO Larry Powalisz expresó su confianza en que la experiencia de la Dra. Sher será invaluable a medida que ADIA expanda su división médica y busque proporcionar atención de primer nivel a los pacientes con EM.
ADIA Nutrition Inc (OTC Pink: ADIA)는 모니카 셔 박사를 의료 부문의 이사 중 한 명으로 임명했습니다. 셔 박사는 다발성 경화증(MS) 환자를 위한 자가 조혈모세포 이식(aHSCT) 프로그램의 정책과 절차를 수립하는 데 중요한 역할을 할 것입니다. 내과 배경을 가진 셔 박사는 MS를 위한 aHSCT 치료를 발전시키는 데 광범위한 경험을 가지고 있습니다.
특별한 협의에 따라 셔 박사는 급여 대신 회사의 자본을 받을 것이며, 이는 ADIA의 성공에 대한 그녀의 헌신을 보여줍니다. 그녀는 수행한 각 절차에 대해 보상을 받을 것입니다. CEO 래리 파왈리즈는 셔 박사의 전문성이 ADIA가 의료 부문을 확장하고 MS 환자에게 최고 수준의 치료를 제공하는 것을 목표로 하는 데 매우 가치있을 것이라고 확신했습니다.
ADIA Nutrition Inc (OTC Pink: ADIA) a nommé Dr. Monica Sher comme l'un des directeurs de sa division médicale. Dr. Sher jouera un rôle important dans l'établissement des politiques et procédures pour le programme de transplantation de cellules souches hématopoïétiques autologues (aHSCT) pour les patients atteints de sclérose en plaques (SEP). Avec sa formation en médecine interne, Dr. Sher apporte une vaste expérience pour faire avancer les thérapies aHSCT pour la SEP.
Dans un accord notable, Dr. Sher recevra des actions de l'entreprise au lieu d'un salaire, ce qui démontre son engagement envers le succès d'ADIA. Elle sera rémunérée par procèdure réalisée. Le PDG Larry Powalisz a exprimé sa confiance que l'expertise de Dr. Sher sera inestimable alors qu'ADIA élargit sa division médicale et vise à fournir des soins de premier ordre aux patients atteints de SEP.
ADIA Nutrition Inc (OTC Pink: ADIA) hat Dr. Monica Sher als eine der Direktoren seiner medizinischen Abteilung ernannt. Dr. Sher wird eine wichtige Rolle bei der Festlegung von Richtlinien und Verfahren für das autologe hämatopoetische Stammzelltransplantation (aHSCT)-Programm für Patienten mit Multipler Sklerose (MS) spielen. Mit ihrem Hintergrund in der Inneren Medizin bringt Dr. Sher umfangreiche Erfahrung mit, um aHSCT-Therapien für MS voranzutreiben.
In einer bemerkenswerten Vereinbarung wird Dr. Sher Aktien des Unternehmens anstelle eines Gehalts erhalten, was ihr Engagement für den Erfolg von ADIA zeigt. Sie wird für jedes durchgeführte Verfahren entschädigt. CEO Larry Powalisz äußerte Vertrauen, dass die Expertise von Dr. Sher von unschätzbarem Wert sein wird, während ADIA seine medizinische Abteilung erweitert und darauf abzielt, Patienten mit MS eine erstklassige Versorgung zu bieten.
- Appointment of Dr. Monica Sher as Director of Medical Division, bringing expertise in Internal Medicine
- Focus on developing Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis patients
- Dr. Sher's compensation structure aligns with company success, receiving equity instead of salary
- None.
Winter Park, Florida--(Newsfile Corp. - August 20, 2024) - ADIA Nutrition Inc. (OTC Pink: ADIA) has appointed Dr. Monica Sher as one of the Directors of its Medical Division, where she will be instrumental in helping to establish the policies and procedures for the company's Autologous Hematopoietic Stem Cell Transplantation (aHSCT) program for Multiple Sclerosis (MS) patients.
Dr. Monica Sher
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/220402_2-1-768x960.jpg
Following a comprehensive search and selection process, Dr. Sher was chosen for her extensive experience and expertise in the field of medicine. With a background in Internal Medicine and a passion for health and wellness, she is well-suited to assist in leading ADIA Nutrition's efforts in advancing aHSCT therapies for MS.
Dr. Sher expressed her excitement about joining ADIA Nutrition Inc., stating, "I am honored to become one of the directors of ADIA's Medical Division. This opportunity aligns perfectly with my passion for improving the lives of patients through stem cell therapy and cutting-edge medical interventions like aHSCT. I look forward to collaborating with the talented team at ADIA Nutrition to drive innovation and deliver exceptional care to our patients."
Larry Powalisz, CEO of ADIA Nutrition Inc., welcomed Dr. Sher to the team, saying, "We are thrilled to have Dr. Sher join us. Her knowledge and expertise in internal medicine and commitment to advancing Stem Cell treatment for MS through aHSCT will be invaluable as we continue to grow and expand our medical division. We are confident that Dr. Sher will be a great asset to our company and will aid ADIA in providing the highest level of care to our patients."
In a unique arrangement, Dr. Sher has agreed to receive equity in the company in exchange for her directorial role, opting not to receive a salary. Instead, she will be compensated per each procedure, highlighting her dedication to the company's success and the advancement of medical treatment for MS.
For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.biolete.com
Website: www.cementfactory.com
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/220402
FAQ
What is ADIA Nutrition Inc's new medical program focusing on?
Who has ADIA Nutrition Inc appointed to its Medical Division?
How will Dr. Monica Sher be compensated in her role at ADIA Nutrition Inc?
What is Dr. Monica Sher's background and expertise?
